vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and GAXOS.AI INC. (GXAI). Click either name above to swap in a different company.
bioAffinity Technologies, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.2M, roughly 1.3× GAXOS.AI INC.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -197.0%, a 119.7% gap on every dollar of revenue. On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs -27.8%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
BIAF vs GXAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.2M |
| Net Profit | $-3.1M | $-957.9K |
| Gross Margin | — | — |
| Operating Margin | -196.9% | -99.0% |
| Net Margin | -197.0% | -77.2% |
| Revenue YoY | -27.8% | 94996.3% |
| Net Profit YoY | -5.7% | -15.1% |
| EPS (diluted) | $-3.59 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $1.2M | ||
| Q3 25 | $1.4M | $498.3K | ||
| Q2 25 | $1.3M | $171.0K | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $2.2M | — | ||
| Q3 24 | $2.4M | — | ||
| Q2 24 | $2.4M | $0 | ||
| Q1 24 | $2.4M | — |
| Q4 25 | $-3.1M | $-957.9K | ||
| Q3 25 | $-5.1M | $-1.0M | ||
| Q2 25 | $-4.1M | $-749.4K | ||
| Q1 25 | $-2.7M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $-2.0M | — | ||
| Q2 24 | $-2.1M | $-809.2K | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | -196.9% | -99.0% | ||
| Q3 25 | -158.6% | -263.9% | ||
| Q2 25 | -198.2% | -574.8% | ||
| Q1 25 | -141.7% | — | ||
| Q4 24 | -133.5% | — | ||
| Q3 24 | -84.0% | — | ||
| Q2 24 | -87.1% | — | ||
| Q1 24 | -80.8% | — |
| Q4 25 | -197.0% | -77.2% | ||
| Q3 25 | -349.3% | -201.0% | ||
| Q2 25 | -319.9% | -438.3% | ||
| Q1 25 | -143.5% | — | ||
| Q4 24 | -134.4% | — | ||
| Q3 24 | -85.1% | — | ||
| Q2 24 | -88.0% | — | ||
| Q1 24 | -81.5% | — |
| Q4 25 | $-3.59 | $-0.13 | ||
| Q3 25 | $-4.74 | $-0.14 | ||
| Q2 25 | $-0.17 | $-0.11 | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-17.27 | — | ||
| Q3 24 | $-4.84 | — | ||
| Q2 24 | $-0.19 | $-0.72 | ||
| Q1 24 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $840.5K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $13.1M |
| Total Assets | $11.0M | $13.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $840.5K | ||
| Q3 25 | $7.7M | — | ||
| Q2 25 | $802.8K | — | ||
| Q1 25 | $444.7K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $756.6K | — | ||
| Q2 24 | $801.3K | $4.5M | ||
| Q1 24 | $2.5M | — |
| Q4 25 | $7.3M | $13.1M | ||
| Q3 25 | $8.9M | $14.1M | ||
| Q2 25 | $-2.1M | $15.0M | ||
| Q1 25 | $1.4M | — | ||
| Q4 24 | $2.6M | — | ||
| Q3 24 | $3.1M | — | ||
| Q2 24 | $3.4M | $4.7M | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $11.0M | $13.4M | ||
| Q3 25 | $11.5M | $14.3M | ||
| Q2 25 | $4.8M | $15.4M | ||
| Q1 25 | $5.5M | — | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $6.6M | — | ||
| Q2 24 | $6.7M | $5.1M | ||
| Q1 24 | $8.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-733.1K |
| Free Cash FlowOCF − Capex | $-2.6M | — |
| FCF MarginFCF / Revenue | -160.7% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $-733.1K | ||
| Q3 25 | $-2.5M | $-1.1M | ||
| Q2 25 | $-2.6M | $-716.9K | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-1.5M | $-738.5K | ||
| Q1 24 | $-2.3M | — |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.5M | — | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.4M | — |
| Q4 25 | -160.7% | — | ||
| Q3 25 | -171.8% | — | ||
| Q2 25 | -209.6% | — | ||
| Q1 25 | -91.3% | — | ||
| Q4 24 | -76.0% | — | ||
| Q3 24 | -73.1% | — | ||
| Q2 24 | -65.1% | — | ||
| Q1 24 | -99.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 1.7% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
